Eduardo Uchiyama, MD
Retina Specialist · Ft Lauderdale, FLNPI 1891973673
Payments from drug & device makers
Across 1,006 payments — averaging $4100.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$2M
- Ocular Therapeutix, Inc.$668K
- Novartis$652K
- Bayer$153K
- Janssen Research & Development, LLC$144K
- Regeneron Healthcare Solutions, Inc.$114K
- plus $382K from 24 others
Across 1 payment — averaging $11,482 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$11K
What the payments were for
- Consulting fees$66,56519%
- Speaking & faculty fees$244,48869%
- Travel & lodging$27,9348%
- Food & beverage$16,9345%
- Education$1410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 198 | $2,010,924 |
| Ocular Therapeutix, Inc. | 102 | $668,005 |
| Novartis | 52 | $652,363 |
| Bayer | 5 | $153,290 |
| Janssen Research & Development, LLC | 43 | $143,593 |
| Regeneron Healthcare Solutions, Inc. | 151 | $114,499 |
| Regeneron | 140 | $98,129 |
| Apellis Pharmaceuticals, Inc. | 55 | $86,358 |
| Eyepoint US, Inc. | 29 | $59,801 |
| Bausch & Lomb Americas Inc. | 37 | $28,019 |
| Boehringer Ingelheim | 5 | $25,980 |
| ANI Pharmaceuticals, Inc. | 20 | $24,384 |
| Alimera Sciences, Inc. | 32 | $16,091 |
| Astellas Pharma Global Development | 8 | $12,171 |
| Genentech USA, Inc. | 39 | $10,576 |
| GSK | 2 | $4,820 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $4,056 |
| AbbVie(2 entities) | 20 | $3,366 |
| Neurotech Pharmaceuticals, Inc. | 2 | $3,121 |
| Astellas Pharma US Inc | 9 | $2,426 |
| Boehringer Ingelheim International GmbH | 24 | $1,534 |
| Mallinckrodt Hospital Products Inc. | 10 | $382 |
| Coherus Oncology, Inc. | 3 | $178 |
| Alcon | 2 | $151 |
| Mallinckrodt Enterprises LLC | 5 | $144 |
| Dutch Ophthalmic, USA | 2 | $143 |
| Sandoz | 3 | $101 |
| Aerie Pharmaceuticals, Inc. | 1 | $100 |
| Kala Pharmaceuticals, Inc. | 1 | $20 |
| Harrow Eye, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$79,271
- Syfovre$77,226
- EYLEA HD$38,423
- XIPERE$28,554
- BEOVU$23,766
- YUTIQ$21,842
- Iluvien$14,786
- OZURDEX$2,771
- BLENREP$2,600
- Lucentis$2,223
- PURIFIED CORTROPHIN GEL$606
- Non-Covered Product$417
- ACTHAR$250
- VABYSMO$166
- Clareon$132
- Izervay$126
- XEN GLAUCOMA TREATMENT SYSTEM$124
- DURYSTA$123
- BUPARLISIB$122
- Cimerli$106
How this compares
$4,124,741 in reported general payments places this provider in the 95th percentile of 118 retina specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IlevroNepafenac | 81 | $34,605 |
| Bromfenac Sodium | 151 | $19,437 |
| Difluprednate | 113 | $11,578 |
| Prednisolone Acetate | 109 | $5,770 |
| ProlensaBromfenac Sodium | 12 | $4,282 |
| ValacyclovirValacyclovir Hcl | 68 | $3,819 |
| Mycophenolate Mofetil | 23 | $933 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 48 | $753 |
| Atropine Sulfate | 12 | $625 |
| MethotrexateMethotrexate Sodium | 22 | $460 |
| Dorzolamide Hcl | 20 | $404 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 43 | $358 |
| Timolol Maleate | 17 | $212 |
| Latanoprost | 19 | $153 |
| Brimonidine Tartrate | 12 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisIlevro | $652,363 | $34,60581 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $4,056 | $4,28212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 118 retina specialist providers in Florida.
Other retina specialist in Ft Lauderdale
- Mario del CidFt Lauderdale$44K
- Ryan ShieldsFt Lauderdale$10K
- Barry TaneyFt Lauderdale$6K
- Darin GoldmanFt Lauderdale$6K
- Shailesh GuptaDeerfield Beach$18.8M
- Vrinda HershbergerMelbourne$8.2M
- Sunil GuptaPensacola$8.1M
- Stuart BurgessPlantation$4.6M
- Drew BawcombeDeerfield Beach$2M
- Dana DeupreeSpring Hill$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.